GSA Capital Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$295K	Buy	+10,927	New	+$367K	0.02%	1261
2025 Q4	–	Sell	-41,771	Closed	-$1.18M	–	2020
2025 Q3	$1.18M	Buy	41,771 +850	+2%	+$25.4K	0.1%	300
2025 Q2	$766K	Sell	40,921 -3,765	-8%	-$71.4K	0.05%	632
2025 Q1	$804K	Buy	+44,686	New	+$907K	0.07%	483
2024 Q3	–	Sell	-90,245	Closed	-$742K	–	1948
2024 Q2	$742K	Sell	90,245 -47,708	-35%	-$499K	0.05%	716
2024 Q1	$2.04M	Sell	137,953 -4,751	-3%	-$64K	0.16%	96
2023 Q4	$2.07M	Buy	142,704 +45,560	+47%	+$466K	0.17%	107
2023 Q3	$1.05M	Buy	97,144 +61,281	+171%	+$737K	0.09%	368
2023 Q2	$463K	Buy	35,863 +3,423	+11%	+$46.3K	0.05%	791
2023 Q1	$428K	Buy	32,440 +22,913	+241%	+$364K	0.04%	814
2022 Q4	$143K	Buy	+9,527	New	+$87.3K	0.02%	1254
2021 Q4	–	Sell	-11,504	Closed	-$418K	–	1740
2021 Q3	$418K	Buy	+11,504	New	+$453K	0.04%	806
2021 Q2	–	Sell	-1,604	Closed	-$55K	–	1557
2021 Q1	$55K	Buy	+1,604	New	+$63.5K	0.01%	1027
2020 Q3	–	Sell	-8,443	Closed	-$155K	–	1366
2020 Q2	$155K	Sell	8,443 -14,112	-63%	-$254K	0.09%	405
2020 Q1	$352K	Sell	22,555 -1,994	-8%	-$42.4K	0.09%	381
2019 Q4	$525K	Buy	24,549 +4,436	+22%	+$91.3K	0.06%	616
2019 Q3	$376K	Buy	+20,113	New	+$416K	0.05%	735
2018 Q4	–	Sell	-2,790	Closed	-$90K	–	1679
2018 Q3	$90K	Buy	+2,790	New	+$83.7K	0.01%	1567
2014 Q2	–	Sell	-1,328	Closed	-$52K	–	1937
2014 Q1	$52K	Buy	+1,328	New	+$47.3K	﹤0.01%	1513